Literature DB >> 23404364

Polymorphisms in the VEGFA promoter are associated with susceptibility to hepatocellular carcinoma by altering promoter activity.

Xiaopan Wu1, Zhenhui Xin, Wei Zhang, Jia Wu, Kangmei Chen, Huifen Wang, Xilin Zhu, Liping Pan, Zhuo Li, Hui Li, Ying Liu.   

Abstract

Accumulated evidences indicate that single nucleotide polymorphisms (SNP) in angiogenesis and tumorigenesis related genes are associated with risk of hepatocellular carcinoma (HCC). Vascular endothelial growth factor A (VEGFA), one of the most significant mediators of angiogenesis, plays an important role in carcinogenesis and development via promoting tumor growth. We carried out a two-stage association study in 1,838 chronic hepatitis B (CHB) patients and 1,207 hepatitis B virus (HBV) related HCC patients in Han Chinese populations from Beijing, Guangxi and Jiangsu. We systematically screened polymorphisms in the VEGFA gene and examined the association between the SNPs and susceptibility to HCC. Functional analyses were conducted to verify biological significances of associated SNPs. We identified two promoter SNPs (rs833061 and rs1570360) were associated with susceptibility to HCC (rs833061: ptrend  = 0.008 in Youan_Beijing samples, ptrend  = 0.01 in Guangxi samples, ptrend  = 0.01 in Jiangsu samples. rs1570360: ptrend  = 0.00003 in Youan_Beijing samples, ptrend  = 0.006 in Guangxi samples, ptrend  = 0.02 in Jiangsu samples). These two SNPs were further validated in four independent groups of major HBV outcomes, indicating rs833061 and rs1570360 may associate exclusively to HCC. Functional analyses show that CA haplotype constructed by rs833061 and rs1570360 had higher luciferase activity compared with TG haplotype (p < 0.05). A 18 bp insert/del polymorphism was in absolute linkage disequilibrium (LD) with rs833061. The 18 bp insert allele created a Sp1 binding site. We observed higher VEGFA transcription in peripheral blood of HCC patients compared with CHB patients and healthy individuals (p < 0.05). These findings indicate that VEGFA promoter SNPs may contribute to susceptibility of HCC by altering promoter activity.
Copyright © 2013 UICC.

Entities:  

Keywords:  VEGFA; hepatocellular carcinoma; promoter activity; realtime PCR; single nucleotide polymorphisms

Mesh:

Substances:

Year:  2013        PMID: 23404364     DOI: 10.1002/ijc.28109

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Liver cancer-related gene CYP2E1 expression in HBV transgenic mice with acute liver injury.

Authors:  Chun Zhang; Qin Wei; Tao Jiang; Xi Shou; Zhi-Qiang Li; Hao Wen
Journal:  Tumour Biol       Date:  2013-12-08

2.  Impact of VEGFA promoter polymorphisms on esophageal cancer risk in North-West Indians: a case-control study.

Authors:  Kamlesh Guleria; Simranjot Kaur; Deepanshi Mahajan; Vasudha Sambyal; Meena Sudan; Manjit Singh Uppal
Journal:  Genes Genomics       Date:  2022-06-29       Impact factor: 2.164

3.  The -1154 G/A VEGF gene polymorphism is associated with the incidence of basal cell carcinoma in patients from northern Poland.

Authors:  Michał Sobjanek; Monika Zabłotna; Aleksandra Lesiak; Igor Michajłowski; Aneta Szczerkowska-Dobosz; Małgorzata Sokolowska-Wojdylo; Roman Nowicki
Journal:  Arch Dermatol Res       Date:  2014-06-06       Impact factor: 3.017

4.  Role of VEGFA gene polymorphisms in colorectal cancer patients who treated with bevacizumab.

Authors:  Wei Cui; Feng Li; Qiang Yuan; Gang Chen; Cailing Chen; Bo Yu
Journal:  Oncotarget       Date:  2017-11-06

5.  Difference of polymorphism VEGF-gene rs699947 in Indonesian chronic liver disease population.

Authors:  Neneng Ratnasari; Siti Nurdjanah; Ahmad Hamim Sadewa; Mohammad Hakimi; Yoshihiko Yano
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

6.  Association of VEGFA polymorphisms with susceptibility and clinical outcome of hepatocellular carcinoma in a Chinese Han population.

Authors:  Fei Liu; Limei Luo; Yonggang Wei; Wentao Wang; Tianfu Wen; Jiayin Yang; Mingqing Xu; Bo Li
Journal:  Oncotarget       Date:  2017-03-07

7.  Downregulation of CRABP2 Inhibit the Tumorigenesis of Hepatocellular Carcinoma In Vivo and In Vitro.

Authors:  Qingmin Chen; Ludong Tan; Zhe Jin; Yahui Liu; Ze Zhang
Journal:  Biomed Res Int       Date:  2020-06-24       Impact factor: 3.411

8.  Associations between twelve common gene polymorphisms and susceptibility to hepatocellular carcinoma: evidence from a meta-analysis.

Authors:  Yi Quan; Jun Yang; Tao Qin; Yufang Hu
Journal:  World J Surg Oncol       Date:  2019-12-12       Impact factor: 2.754

9.  VEGF Polymorphisms Related to Higher Serum Levels of Protein Identify Patients with Hepatocellular Carcinoma.

Authors:  Maria Eduarda Lopes Baitello; Graciele Domitila Tenani; Rafael Fernandes Ferreira; Victor Nogueira; Marcela Augusta de Souza Pinhel; Rita de Cássia Martins Alves da Silva; Renato Ferreira da Silva; Patrícia da Silva Fucuta; Moacir Fernandes de Godoy; Dorotéia Rossi Silva Souza
Journal:  Can J Gastroenterol Hepatol       Date:  2016-08-31

10.  Direct inhibition of the TLR4/MyD88 pathway by geniposide suppresses HIF-1α-independent VEGF expression and angiogenesis in hepatocellular carcinoma.

Authors:  Cheng Zhang; Ning Wang; Hor-Yue Tan; Wei Guo; Feiyu Chen; Zhangfeng Zhong; Kwan Man; Sai Wah Tsao; Lixing Lao; Yibin Feng
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.